Evista優雅健

Evista

raloxifene

Manufacturer:

Alvogen

Distributor:

Firma Chun Cheong
/
International Med
Concise Prescribing Info
Contents
Raloxifene HCl
Indications/Uses
Treatment & prevention of osteoporosis in postmenopausal women. Reduction in the risk of invasive breast cancer in postmenopausal women w/ osteoporosis &/or at high risk of invasive breast cancer.
Dosage/Direction for Use
1 tab daily.
Administration
May be taken with or without food.
Contraindications
Women of childbearing potential; active or history of venous thromboembolic events; severe hepatic impairment including cholestasis; severe renal impairment; unexplained uterine bleeding. Endometrial cancer.
Special Precautions
History of stroke or other stroke risk factors eg, transient ischemic attack or atrial fibrillation. Co-administration w/ systemic estrogens is not recommended. In patient w/ history of oral oestrogen-induced hypertriglyceridaemia, monitor serum triglycerides. Complete breast cancer treatment before initiating raloxifene.
Adverse Reactions
Hot flushes, flu syndrome, leg cramps, peripheral oedema, venous thromboembolic events eg, DVT, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis.
Drug Interactions
Should not be co-administered w/ cholestyramine.
ATC Classification
G03XC01 - raloxifene ; Belongs to the class of selective estrogen receptor modulators.
Presentation/Packing
Form
Evista film-coated tab 60 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in